Abstracts tagged "Biologic drugs"

Abstract Number: 404 • 2016 ACR/ARHP Annual Meeting
Disease Activity and Damage in Juvenile Idiopathic Arthritis: Comparison Between “Methotrexate” and “Biologic” Era
Gabriella Giancane¹, Valentina Muratore², Valentina Marzetti³, Neus Quilis⁴, Belen Serrano⁵, Alessandra Alongi⁵, Adele Civino⁶, Lorenzo Quartulli⁷, Alessandro Consolaro², Alberto Martini² and Angelo Ravelli², ¹Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ²Istituto Giannina Gaslini, Genoa, Italy, ³IRCCS G. Gaslini, Genoa, Italy, ⁴Pediatria II Reumatologia, IRCCS G. Gaslini, Genoa, Italy, ⁵Pediatria II, IRCCS G. Gaslini, Genoa, Italy, ⁶Azienda Ospedaliera Card G Panico, Tricase, Italy, ⁷UOC Pediatria - AO "Card.G.Panico", Tricase, Italy
Background/Purpose: The introduction of biologic agents at the beginning of the 2000s has represented a major advance in the management of juvenile idiopathic arthritis (JIA).…
Abstract Number: 2440 • 2016 ACR/ARHP Annual Meeting
First Results from the Prospective German Pregnancy Register
Rebecca Fischer-Betz¹, Christina Bungartz², Jutta Richter¹, Angela Zink³, Matthias Schneider¹, Anja Weiss², Joachim Listing⁴ and Anja Strangfeld⁵, ¹Department of Rheumatology & Hiller Research Unit, Heinrich-Heine-University, Duesseldorf, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³Epidemiology Unit, German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ⁴German Rheumatism Research Center, Berlin, Germany, ⁵Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: There is limited evidence on the safety of treatment during pregnancy and lactation. With the increasing number of new therapeutic options for inflammatory rheumatic…
Abstract Number: 526 • 2016 ACR/ARHP Annual Meeting
Changes in the Functional Status of the Rheumatoid Arthritis (RA) Population over the Biologic Era
Brenna Brady¹, Nicole Gerlanc¹, David Collier² and Bradley S. Stolshek³, ¹Health Analytics, LLC, Columbia, MD, ²Amgen Inc., Thousand Oaks, CA, ³Amgen, Thousand Oaks, CA
Background/Purpose: In 1998, the first biologic disease modifying antirheumatic drug was approved in the United States for the treatment of RA. Since that time, biologics…
Abstract Number: 2516 • 2016 ACR/ARHP Annual Meeting
Concomitant Use of Oral Vs. Subcutaneous Methotrexate at Biologic Initiation: A Comparison of Biologic Treatment Survival in a Rheumatoid Arthritis Cohort
Carter Thorne¹, Mohammad Movahedi², Angela Cesta², Xiuying Li², Emmanouil Rampakakis³, John S. Sampalis⁴ and Claire Bombardier⁵, ¹University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³JSS Medical Research, St-Laurent, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Previous studies have shown differences in the effectiveness and survival of subcutaneous vs. oral methotrexate. Furthermore, concurrent methotrexate therapy has been shown to enhance…
Abstract Number: 620 • 2016 ACR/ARHP Annual Meeting
Clinical Activity, Ultrasound Assessment and Drug Monitoring in Rheumatoid Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
José Miguel Senabre-Gallego¹, José Rosas¹, Francisca Llinares-Tello², Mariana Marco-Mingot², Ana Pons¹, Xavier Barber³, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Catalina Cano¹, Marisa Lorente⁴, Marina Sanchís³, Juan Molina², Mario García-Carrasco⁵ and AIRE-MB, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ³CIO, Universidad Miguel Hernández, Elche, Spain, ⁴Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ⁵Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: To assess clinical activity, ultrasound synovitis and drug levels in rheumatoid arthritis (RA) patients receiving anti-TNFα therapy with extended interval of administration (EIA). Methods:…
Abstract Number: 2528 • 2016 ACR/ARHP Annual Meeting
Predictors of Long Term Survival of Low-Dose Etanercept: An Observational Study
Francesca Ometto¹, Bernd Raffeiner^2,3, Costantino Botsios², Davide Astorri⁴, Lara Friso², Livio Bernardi⁵, Leonardo Punzi⁶ and Andrea Doria², ¹Rheumatology Unit, Department of Medicine - DIMED, University of Padova, PADOVA, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ³Rheumatology Unit, Internal Medicine, General Hospital of Bolzano, Bolzano, Italy, ⁴Rheumatology Unit, Department of Medicine - DIMED, University of Padova, padova, Italy, ⁵Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, ⁶Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy
Background/Purpose: The objective of the study was to investigate long-term survival of low-dose etanercept (ETN) (25 mg weekly) and possible predictors of survival. Methods: We…
Abstract Number: 626 • 2016 ACR/ARHP Annual Meeting
Switching Biologic Therapy in a Population of Rheumatoid Arthritis Patients
Branca Souza¹, Juliana Valim², Fernanda Chaer³, Fernanda Guimarães⁴ and Verônica Lima⁵, ¹Reumatologia, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ²Rheumatology, Santa Casa de São Paulo, São Paulo, Brazil, ³Rheumatology, Irmandade da Santa Casa de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Irmandade Santa Casa de Misericordia de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Irmandade Santa Casa de São Paulo, São Paulo, Brazil
Background/Purpose: Evaluate the reason of exchange of biologic therapy in patients with rheumatoid arthritis and describe the frequency of remission or low activity, according to…
Abstract Number: 2529 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Marina Machado¹, Cristiano S. Moura², Hassan Behlouli¹, Jeffrey R. Curtis³ and Sasha Bernatsky⁴, ¹Department of Medicine, McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor approved in the USA in November 2012 for the treatment of rheumatoid arthritis (RA). As the…
Abstract Number: 635 • 2016 ACR/ARHP Annual Meeting
Factors Associated to Lack of Adherence to Subcutaneous Biological Medications in Patients with Rheumatoid Arthritis from Spain. Arco Study
Jaime Calvo-Alen¹, Indalecio Monteagudo², Georgina Salvador Alarcón³, Enrique Raya Álvarez⁴, Loreto Carmona⁵, Luis Cea-Calvo⁶ and Carlos Marras Fernandez-Cid⁷, ¹Rheumatology, Txagorritxu Hospital, Araba, Vitoria, Vitoria, Spain, ²Rheumatology Unit, HGU Gregorio Marañón, Madrid, Madrid, Spain, ³Rheumatology, HU Mutua de Terrassa, Barcelona, Terrassa, Spain, ⁴Rheumatology, Hospital Clínico San Cecilio, Granada, Spain, ⁵Instituto de Salud Musculoesquelética, Madrid, Spain, ⁶Medical Affairs Department, Merck Sharp & Dohme, Madrid, Spain, ⁷Rheumatology, Hospital Virgen de la Arrixaca, Murcia, Spain
Background/Purpose: To investigate the variables associated to lack of adherence to subcutaneous (SC) biological drug in patients with rheumatoid arthritis (RA) after 1 year of…
Abstract Number: 2540 • 2016 ACR/ARHP Annual Meeting
The Longitudinal Impact of Biologic Use on Disability within a RA Registry
N A Shadick¹, Nicole Gerlanc², M Frits¹, Bradley S. Stolshek³, Brenna Brady², Christine Iannaccone⁴, David Collier⁵, Jing Cui⁶, Alex Mutebi⁷ and Michael Weinblatt⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Health Analytics, LLC, Columbia, MD, ³Amgen, Thousand Oaks, CA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Global Health Economics, Amgen, Thousand Oaks, CA
Background/Purpose: Biologics have become the standard of care for treating moderate to severe rheumatoid arthritis (RA) in patients with an inadequate response to small molecule…
Abstract Number: 636 • 2016 ACR/ARHP Annual Meeting
Prospective, Intervention, Multicenter Study of Utility of Biologic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases (34-week descriptive data)
Iñigo Gorostiza¹, Eduardo Úcar Angulo², Catalina Gómez Arango², Clara Eugenia Perez³, Juan Ramon De Dios⁴, Belen Alvarez⁴, Ana Ruibal Escribano^4,5, Claudia Stoye⁴, Margarida Vasques⁴, Joaquin Belzunegui Otano⁶, Antonio Escobar⁷, Ziortza Trancho⁸, Ainhoa Ruiz del Agua⁹, Lorena Del Rio⁹, Antonio Martínez⁹ and Daniel Nagore⁹, ¹Research Department, Hospital Universitario de Basurto, Bilbao, Spain, ²Rheumatology, Rheumatology Department, Basurto University Hospital, Bilbao, Spain, ³Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ⁴Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁵Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ⁶Donostia University Hospital, San Sebastian, Spain, ⁷Unidad de Investigación, Red de Investigación en Servicios de Salud en enfermedades crónicas (REDISSEC), Hospital Universitario de Basurto, Bilbao, Spain, ⁸Unidad de Investigación, Hospital Universitario de Basurto, Bilbao, Spain, ⁹R&D, Progenika-Grifols, Derio, Spain
Background/Purpose: Adalimumab (ADL) dose tapering based on clinical assessment is a usual practice especially in patients who have achieved clinical remission. The primary aim of…
Abstract Number: 2551 • 2016 ACR/ARHP Annual Meeting
Impact of Multmorbidity on Disability and Disease Activity over Time in Patients with RA Taking Biologics: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Jennifer Humphreys¹, Kath Watson², Mark Lunt^2,3, Deborah P.M. Symmons^2,4,5, Kimme L. Hyrich^2,4,6 and the BSRBR-RA, ¹Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁴Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁶Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Multimorbidity is increasingly prevalent in western populations and has the potential to influence disease specific outcomes. Rheumatoid arthritis (RA) is a chronic inflammatory…
Abstract Number: 949 • 2016 ACR/ARHP Annual Meeting
Comparison of Treatment Response, Remission Rate and Drug Adherence in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Etanercept, Adalimumab or Tocilizumab
Gerd Horneff^1,2, Ariane Klein³, Kirsten Minden^4,5, Hans-Iko Huppertz⁶, Frank Weller-Heinemann⁷, Jasmin B. Kuemmerle-Deschner⁸, Johannes Peter Haas⁹ and Toni Hospach¹⁰, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ³Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁴Epidemiology, Charite, DRFZ, Berlin, Germany, ⁵Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁶Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ⁷Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁸Universitätsklinikum Tübingen, Klinik fuer Kinder- und Jugendmedizin, Tübingen, Germany, ⁹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ¹⁰Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany
Background/Purpose: Treatment response, remission rates and compliance in polyarticular JIA patients treated with adalimumab(ADA), etanercept(ETA), or tocilizumab(TCZ) were analyzed in clinical practice. Methods: Data from the German BIKER…
Abstract Number: 2617 • 2016 ACR/ARHP Annual Meeting
Economic Burden of Non-Responders to Biologic DMARD Treatments in Rheumatoid Arthritis
Vibeke Strand¹, Namita Tundia², Yan Song³, Dendy Macaulay⁴ and Mahesh Fuldeore⁵, ¹School of Medicine, Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²AbbVie, Inc., North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Analysis Group, Inc., New York, NY, ⁵AbbVie, Inc, North Chicago, IL
Background/Purpose: Biologic agents are effective in treating patients with rheumatoid arthritis (RA); however, some patients either fail to respond or lose response over time. This…
Abstract Number: 511 • 2015 ACR/ARHP Annual Meeting
Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
KAZUYUKI YOSHIZAKI, Organic Fine Chemicals, The Institute of Scientific and Industrial Research, Osaka University, Suita, Japan
Background/Purpose: In clinical practice in rheumatoid arthritis (RA), it has been noted that each anti-rheumatic therapy delivers a different outcome for individual RA patients and…

« Previous Page
1
…
6
7
8
9
10
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].